Purple Biotech Ltd
Research Purple Biotech Ltd (PPBT) on Bullrun: market cap USD 1.54M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPPBT
- ExchangeNASDAQ
- CountryIsrael
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.54M
- Financial periodQ2 2026
- RevenueUSD 0
- Net incomeUSD 441.00K
- Free cash flow-USD 2.51M
Valuation Snapshot
latest market cap is USD 1.54M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 26.39M | -USD 5.66M | n/a | -546 | USD 8.72M | USD 244.00K | USD 9.71M |
| FY2024 | USD 0 | -USD 7.24M | -USD 14.37M | n/a | -563.79 | USD 7.40M | USD 183.00K | USD 32.86M |
| FY2023 | n/a | n/a | n/a | n/a | -47.7 | USD 14.49M | USD 351.00K | USD 34.21M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 1.54M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 6.12M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 12.13M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 19.20M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 25.42M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 69.24M | n/a | n/a | n/a |
About Purple Biotech Ltd
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Purple Biotech Ltd's market cap?
Purple Biotech Ltd's market capitalization is USD 1.54M.
What does Purple Biotech Ltd do?
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States.